ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025
Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating tumour cells and circulating tumour DNA in head and neck cancer: from molecular insights to clinical impact.Cancer metastasis reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough immunotherapy improves the overall survival (OS) of patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), only 15% to 20% of patients derive a long-term benefit. We hypothesized that ctDNA kinetics during immunotherapy, with or without chemotherapy, could predict treatment efficacy in patients with R/M SCCHN. EXPERIMENTAL
designUsing a personalized, tumor-informed ctDNA assay, we evaluated ctDNA kinetics from pre- to on-treatment (6-10 weeks after treatment initiation) time points. The primary endpoint was the concordance between ctDNA kinetics and best overall response (BOR). Secondary endpoints were the association of ctDNA clearance and kinetics with OS and progression-free survival (PFS).
resultsOf the 41 patients, ctDNA assays were successfully designed for 29, and ctDNA was detected before treatment in 25 patients. ctDNA kinetics was significantly correlated with BOR (P = 0.00032). Patients with unfavorable ctDNA kinetics had significantly worse PFS compared with those with favorable ctDNA kinetics (HR = 16.98; 95% confidence interval, 3.35-86.1; P = 0.0006). Six patients had ctDNA clearance, all of whom presented a complete or partial response as BOR. PFS and OS were significantly improved in patients with ctDNA clearance compared with those without clearance (PFS: P = 0.0006, OS: P = 0.027).
conclusionsctDNA kinetics, assessed with a tumor-informed assay, can predict anti-PD-1 therapy efficacy in R/M SCCHN. Early ctDNA clearance during the initial weeks of immunotherapy seems to be a strong predictive marker for a favorable response, as well as improved PFS and OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.